Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Temporal Dissection of the Effects of Tumour Suppressor Loss on Lung Cancer Progression
EF 2009-10
Résumé
Lung cancer is the leading cause of cancer death in Canada and globally, killing more people than breast, prostate and colorectal cancers combined. Unfortunately, for the majority of Canadians diagnosed with non-small-cell lung cancer (NSCLC), the prognosis remains the same as it did twenty years ago - less than a 5%, 5-yr survival rate. While standard chemotherapies have failed, hope remains. A combination of genetic and biochemical data have identified a number of cancer genes that may be good targets for future chemotherapeutic drugs. Indeed, several recent, high-profile examples of new therapeutics have achieved success in the clinic, where it matters most to the average Canadian.
Despite these successes, these therapies fail to provide clinical benefit for the vast majority of NSCLC patients. The most prevalent mutated oncogenes in human cancers are RAS and BRAF genes, particularly in cases of NSCLC (more than 25%). Yet available data suggest that these mutant oncogenes do not act on their own; rather, they require additional cooperating genes for cancer genesis and progression. The objectives of this proposal are to identify these cooperating genes, to determine how they work at the molecular level, and when they are important in the evolution of a fully malignant, metastatic cell - all of which are paramount to discovering novel effective cancer treatments.
Genetically modified mouse models (GEMMs) are currently the gold standard for whole-organism cancer-modeling. We will make use of our novel GEMMs of human lung cancer to control the site, number and timing of tumour initiation. This will allow us to explore fundamental questions about the genetics of tumour initiation, progression, maintenance and, ultimately, metastasis. Furthermore, these GEMMs of human lung cancer can provide platforms, for both the engineering and validation of targeted therapies, to develop new therapies to alleviate the suffering inflicted by this dreaded disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
200304
Name
Mcdonough Rosalie V
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Temporal Dissection of the Effects of Tumour Suppressor Loss on Lung Cancer Progression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
B-Raf; Cre/Flp Recombination; Genetically Engineered Mouse Models (Gemms); Lung Cancer; Ras Signaling; Retroviral/Lentiviral Technologies; Tumor Suppressors (Ink4a/Arf)
Abstract
Lung cancer is the leading cause of cancer death in Canada and globally, killing more people than breast, prostate and colorectal cancers combined. Unfortunately, for the majority of Canadians diagnosed with non-small-cell lung cancer (NSCLC), the prognosis remains the same as it did twenty years ago - less than a 5%, 5-yr survival rate. While standard chemotherapies have failed, hope remains. A combination of genetic and biochemical data have identified a number of cancer genes that may be good targets for future chemotherapeutic drugs. Indeed, several recent, high-profile examples of new therapeutics have achieved success in the clinic, where it matters most to the average Canadian.
Despite these successes, these therapies fail to provide clinical benefit for the vast majority of NSCLC patients. The most prevalent mutated oncogenes in human cancers are RAS and BRAF genes, particularly in cases of NSCLC (more than 25%). Yet available data suggest that these mutant oncogenes do not act on their own; rather, they require additional cooperating genes for cancer genesis and progression. The objectives of this proposal are to identify these cooperating genes, to determine how they work at the molecular level, and when they are important in the evolution of a fully malignant, metastatic cell - all of which are paramount to discovering novel effective cancer treatments.
Genetically modified mouse models (GEMMs) are currently the gold standard for whole-organism cancer-modeling. We will make use of our novel GEMMs of human lung cancer to control the site, number and timing of tumour initiation. This will allow us to explore fundamental questions about the genetics of tumour initiation, progression, maintenance and, ultimately, metastasis. Furthermore, these GEMMs of human lung cancer can provide platforms, for both the engineering and validation of targeted therapies, to develop new therapies to alleviate the suffering inflicted by this dreaded disease.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mcdonough, Rosalie V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~